ESC Congress 2026 – My Top 20 Lipidology Highlights Shaping the Future of Cardiovascular Prevention – Pablo Corral
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn:
”ESC Congress 2026 | My Top 20 Lipidology Highlights
After an intense few days in Munich — including the opportunity to present our own work — here is my personal selection of the 20 lipid studies and concepts that caught my attention at ESC 2026.
1- VESALIUS-CV | Evolocumab — Earlier, sustained LDL-C lowering translated into clinical benefit, with an important mortality signal.
2- STAREE | Atorvastatin. In adults aged 70 and older, MACE decreased by 30 percent. Age alone should not justify undertreatment.
3- SHASTA-3/4 | Plozasiran. Triglycerides decreased by approximately 80 percent, with fewer acute pancreatitis events.
4. AMUNDSEN | Evolocumab. Immediate post-MI initiation: LDL-C goal was achieved in 82 percent versus 40 percent.
5. KYLO-11 | Lp(a). One siRNA dose reduced Lp(a) by up to approximately 97 percent, with the effect sustained for almost one year.
6. CTX310 | ANGPTL3. One-time CRISPR editing reduced LDL-C and triglycerides by approximately 50 percent.
7. VICTORION-CHALLENGE. Inclisiran substantially outperformed bempedoic acid in lowering LDL-C.
8. CORALreef | Enlicitide. Potent oral PCSK9 inhibition across cardiovascular risk and Lp(a) strata.
9. Lepodisiran. Profound Lp(a) lowering, plus reductions in OxPL-apo(a) and OxPL-apoB.
10. ION775 | APOC3. One dose provided sustained apoC-III and triglyceride lowering.
11. HRS-5346. Oral small-molecule Lp(a) lowering represents an exciting new approach.
12. BRIDGE. Structured combination therapy after ACS markedly improved LDL-C goal attainment.
13. Rivocibart | ANGPTL3. A promising approach for HoFH.
14. AAV8 gene therapy | HoFH. Striking early reductions in LDL-C with gene replacement.
15. PROSPECT II | Lp(a). New links between Lp(a), lipid composition, and high-risk coronary plaque.
16. Lp(a) variability. Lp(a) may be less “static” than traditionally assumed.
17. Remnants and TGRL. More evidence linking remnant cholesterol with residual ASCVD risk.
18. Lp(a) and plaque vulnerability. Imaging further connected Lp(a) with vulnerable plaque phenotypes.
19. Lp(a) after ACS. Timing and clinical context may influence Lp(a) interpretation.
20. Precision lipidology. LDL-C, apoB, Lp(a), APOC3, ANGPTL3, and remnants are becoming therapeutic targets.
My take-home from Munich?
For today: treat earlier, lower and for longer. Use combination therapy when needed.
For tomorrow: pills, followed by combination therapy, followed by RNA therapeutics, and potentially one-time gene editing.
Different technologies. Different targets. Same biology:
Cumulative exposure to atherogenic lipoproteins drives atherosclerosis. Reduce exposure earlier, prevent disease earlier.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 18:12Adil Nawaz: Extended Dual Antiplatelet Therapy After Coronary Stenting
-
Oct 16, 2026, 17:50Elad Asher։ STORM-PE Shows Functional Benefits of Thrombectomy
-
Oct 16, 2026, 17:32Shruthi Narayan: STORM-PE and STRIKE-PE Studies Advance Understanding of Recovery After Pulmonary Embolism
-
Oct 16, 2026, 17:22Wolfgang Miesbach։ What a Near-Perfect FISH Score Fails to See
-
Oct 16, 2026, 17:06Troels Wienecke: Connecting Myeloproliferative Disease and Ischemic Stroke
-
Oct 16, 2026, 17:03Only 5 Days Left to Submit Your Research for EAHAD 2027
-
Oct 16, 2026, 16:48Abdul Rahman: Reticulocyte Count and Bone Marrow Activity
-
Oct 16, 2026, 16:44DOAC Adherence in Stroke Patients With Atrial Fibrillation – International Journal of Stroke
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand